keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis in CKD

keyword
https://www.readbyqxmd.com/read/29676846/generic-sofosbuvir-based-direct-acting-antivirals-in-hepatitis-c-virus-infected-patients-with-chronic-kidney-disease
#1
Manoj Kumar Sharma, Suman Lata Nayak, Ekta Gupta, Ashish Kataria, Shiv K Sarin
BACKGROUND & AIMS: There is scant data on use of sofosbuvir containing directly acting anti-viral (DAA) regimens in chronic kidney disease (CKD) patients. Recently generic versions of DAAs have become available in low income countries including India. The aim of this study was to study the efficacy and safety of generic sofosbuvir in combination with generic ribavirin, ledipasvir, or daclatasvir in HCV infected patients with CKD including patients with advanced CKD (CKD stage 4 or 5 with an estimated glomerular filtration rate (GFR) <30 mL/min or those on dialysis)...
April 20, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29665081/safety-of-sofosbuvir-based-regimens-after-liver-transplantation-longitudinal-assessment-of-renal-function-in-the-prospective-anrs-co23-cupilt-study
#2
R Anty, G Favre, A Coilly, E Rossignol, P Houssel-Debry, C Duvoux, V De Ledinghen, V Di Martino, V Leroy, S Radenne, N Kamar, V Canva, L D'Alteroche, F Durand, J Dumortier, P Lebray, C Besch, A Tran, C M Canivet, D Botta-Fridlund, H Montialoux, C Moreno, F Conti, C Silvain, P Perré, F Habersetzer, A Abergel, M Debette-Gratien, S Dharancy, V L M Esnault, C Fougerou-Leurent, C Cagnot, A Diallo, A Veislinger, H Danjou, D Samuel, G-P Pageaux, J-C Duclos-Vallée
BACKGROUND: In liver transplant recipients with hepatitis C virus recurrence, there is concern about renal safety of sofosbuvir-based regimens. Changes in serum creatinine or in the estimated glomerular filtration rate (eGFR) under treatment are used to look for possible renal toxicity. However, serum creatinine and eGFR are highly variable. AIM: To analyse renal function trajectory with numerous assays of serum creatinine over a long period of time. METHODS: In a multicentre cohort of 139 patients, the eGFR was obtained from serum creatinine using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation...
April 17, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29659605/chronic-kidney-disease-in-the-global-adult-hiv-infected-population-a-systematic-review-and-meta-analysis
#3
Udeme E Ekrikpo, Andre P Kengne, Aminu K Bello, Emmanuel E Effa, Jean Jacques Noubiap, Babatunde L Salako, Brian L Rayner, Giuseppe Remuzzi, Ikechi G Okpechi
INTRODUCTION: The widespread use of antiretroviral therapies (ART) has increased life expectancy in HIV patients, predisposing them to chronic non-communicable diseases including Chronic Kidney Disease (CKD). We performed a systematic review and meta-analysis (PROSPERO registration number CRD42016036246) to determine the global and regional prevalence of CKD in HIV patients. METHODS: We searched PubMed, Web of Science, EBSCO and AJOL for articles published between January 1982 and May 2016...
2018: PloS One
https://www.readbyqxmd.com/read/29600429/efficacy-and-safety-of-ledipasvir-sofosbuvir-for-genotype-1b-chronic-hepatitis-c-patients-with-moderate-renal-impairment
#4
Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota, Hidenori Toyoda, Noritomo Shimada, Hiroshi Abe, Keizo Kato, Korenobu Hayama, Taeang Arai, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Chiaki Kawamoto, Etsuko Iio, Yasuhito Tanaka, Takashi Kumada, Katsuhiko Iwakiri
BACKGROUND/AIM: To evaluate the efficacy and safety of ledipasvir and sofosbuvir therapy for genotype 1b in chronic hepatitis C patients with chronic kidney disease (CKD) stage 3. METHODS: In a multicenter collaborative retrospective study, 706 patients who have received ledipasvir which is NS5A inhibitor, and sofosbuvir 400 mg which is NS5B nucleoside polymerase inhibitor daily for 12 weeks between September 2015 and January 2017 were subjected to this analysis...
March 29, 2018: Hepatology International
https://www.readbyqxmd.com/read/29573131/achieving-sustained-virologic-response-in-liver-transplant-recipients-with-hepatitis-c-decreases-risk-of-decline-in-renal-function
#5
Sanjaya K Satapathy, Kiran Joglekar, Miklos Z Molnar, Bilal Ali, Humberto C Gonzalez, Jason M Vanatta, James D Eason, Satheesh P Nair
BACKGROUND: The effect of anti-viral therapy (AVT) on kidney function in liver transplant (LT) recipients has not been well described despite known association of hepatitis C virus (HCV) infection with chronic kidney disease (CKD). METHODS: We compared the incidence of CKD, and end-stage renal disease (ESRD) in 204 LT recipients with HCV based on treatment response to AVT. RESULTS: The median eGFR at baseline (3 months post-LT) was similar in the SVR (n=145) and non-SVR group (n=59) (69±21 vs...
March 23, 2018: Liver Transplantation
https://www.readbyqxmd.com/read/29560689/does-advanced-chronic-kidney-disease-impact-transjugular-intrahepatic-portosystemic-shunt-efficacy-and-safety
#6
Janesh Lakhoo, Senthil S Gunasekaran, R Peter Lokken, Andrew J Lipnik, Charles E Ray, James T Bui, Ron C Gaba
BACKGROUND AND STUDY AIMS: There are currently limited data available summarizing the clinical outcomes and safety of transjugular intrahepatic portosystemic shunts (TIPS) in cases of advanced chronic kidney disease (CKD). The study aimed to assess efficacy and safety of TIPS in patients with advanced CKD. PATIENTS AND METHODS: Seventeen patients (M :F 8 :9, age 55 years, MELD 24) with grade 4-5 CKD who underwent TIPS for ascites (n = 7) or varices (n = 10) were analyzed...
April 2017: Acta Gastro-enterologica Belgica
https://www.readbyqxmd.com/read/29545888/risk-factors-for-new-onset-chronic-kidney-disease-in-patients-who-have-received-a-liver-transplant
#7
Yuehong Li, Binbin Li, Wei Wang, Jiaxuan Lv
The aim of the present study was to analyze the risk factors for new-onset chronic kidney disease (CKD) in patients who have received a liver transplant. A total of 190 patients who underwent liver transplantation between March 2001 and January 2015 were followed up, and analyzed retrospectively. Sex, age, primary disease, preoperative laboratory findings (hemoglobin, albumin, creatinine and glomerular filtration rate), surgical approach, blood loss during the surgery and transfusion volume, postoperative complications, and the average levels of calcineurin inhibitors (CNIs) (from liver transplantation to the onset of CKD) were analyzed...
April 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29504859/survival-analysis-to-evaluate-associations-between-periodontal-disease-and-the-risk-of-development-of-chronic-azotemic-kidney-disease-in-cats-evaluated-at-primary-care-veterinary-hospitals
#8
Rosalie T Trevejo, Sandra L Lefebvre, Mingyin Yang, Catherine Rhoads, Gary Goldstein, Elizabeth M Lund
OBJECTIVE To examine potential associations between periodontal disease (PD) and the risk of development of chronic azotemic kidney disease (CKD) among cats and determine whether the risk of CKD increases with severity of PD. DESIGN Retrospective cohort study. ANIMALS 169, 242 cats. PROCEDURES Cats were evaluated ≥ 3 times at any of 829 hospitals from January 1, 2002, through June 30, 2013. Cats with an initial diagnosis of PD of any stage (n = 56,414) were frequency matched with cats that had no history or evidence of PD (112,828) by age and year of study entry...
March 15, 2018: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/29491685/nationwide-cohort-study-suggests-that-nucleos-t-ide-analogue-therapy-decreases-dialysis-risk-in-taiwanese-chronic-kidney-disease-patients-acquiring-hepatitis-b-virus-infection
#9
Yi-Chun Chen, Chung-Yi Li, Shiang-Jiun Tsai, Yen-Chun Chen
AIM: To investigate the risk of end-stage renal disease (ESRD) in hepatitis B virus (HBV)-infected patients with chronic kidney disease (CKD) with and without nucleos(t)ide analogue (NA) therapy. METHODS: This nationwide cohort study included 103444 Taiwanese CKD adults without hepatitis C virus infection from the Taiwan Longitudinal Health Insurance Database 2005 between 1997 and 2012. We identified 2916 CKD patients who acquired HBV infection and did not receive NAs (untreated cohort), and they were propensity-matched 1:4 with 11664 uninfected counterparts...
February 28, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29484572/low-dose-sofosbuvir-is-safe-and-effective-in-treating-chronic-hepatitis-c-in-patients-with-severe-renal-impairment-or-end-stage-renal-disease
#10
Sunil Taneja, Ajay Duseja, Arka De, Manu Mehta, Raja Ramachandran, Vivek Kumar, Harbir Singh Kohli, Krishan Lal Gupta, Radha Krishan Dhiman, Yogesh Chawla
BACKGROUND AND AIMS: There is sparse data on the use of Sofosbuvir based directly acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 . We evaluated the safety and efficacy of low-dose Sofosbuvir plus full-dose Daclatasvir in CHC patients with CKD. METHODS: Sixty-five CHC patients with CKD with eGFR less than 30 mL/min/1.73 m2 [54 (83%) patients with ESRD on hemodialysis] were included...
February 26, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29484199/project-help-a-study-protocol-to-pilot-test-a-shared-decision-making-tool-about-treatment-options-for-patients-with-hepatitis-c-and-chronic-kidney-disease
#11
M C Politi, N George, T Li, K M Korenblat, K J Fowler, C Ho, A Liapakis, D Roth, J Yee
Background: Recent advances in treatment have given patients with chronic kidney disease (CKD) access to safer and more effective medications to treat comorbid hepatitis C virus (HCV) infection. Given the variety and complexity of treatment options that depend on patients' clinical characteristics and personal preferences, education and decision support are needed to prepare patients better to discuss treatment options with their clinicians. Methods: Drawing on International Patient Decision Aids Standards guidelines, literature reviews, and guidance from a diverse expert advisory group of nephrologists, hepatologists, and patients, we will develop and test a HCV and CKD decision support tool...
2018: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/29465262/glecaprevir-pibrentasvir-for-treatment-of-hepatitis-c
#12
Andres F Carrion, Paul Martin
Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis...
March 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29427485/treatment-of-hepatitis-c-the-use-of-the-new-pangenotypic-direct-acting-antivirals-in-special-populations
#13
REVIEW
Stanislas Pol, Lucia Parlati
BACKGROUND & AIMS: The recommended combination of pangenotypic direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) associates the co-formulation of 2 or 3 second-generation DAAs. In the so-called "special populations" defined as patients with chronic kidney disease (CKD), HCV/HIV co-infection, HCV/HBV co-infection and an unsuccessful previous DAA regimen, these combinations have a high antiviral potency (sustained virologic response (SVR) > 95%), fair tolerance and a reduced pill burden...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29382678/fatty-liver-index-albuminuria-and-the-association-with-chronic-kidney-disease-a-population-based-study-in-china
#14
Kan Sun, Diaozhu Lin, Feng Li, Yiqin Qi, Wanting Feng, Li Yan, Chaogang Chen, Meng Ren, Dan Liu
OBJECTIVES: The effects of lipid metabolism disorder on renal damage have drawn much attention. Using the fatty liver index (FLI) as a validated indicator of hepatic steatosis, this study aims to provide insight about the possible links between fatty liver and the development of chronic kidney disease (CKD). SETTING: Hospital. PARTICIPANTS: We performed a population-based study on 9436 subjects aged 40 years or older. PRIMARY AND SECONDARY OUTCOME MEASURES: FLI is calculated using an algorithm based on body mass index, waist circumference, triglycerides and γ-glutamyltransferase...
January 30, 2018: BMJ Open
https://www.readbyqxmd.com/read/29377515/impact-of-interferon-free-regimens-on-the-glomerular-filtration-rate-during-treatment-of-chronic-hepatitis-c-in-a-real-life-cohort
#15
M J Álvarez-Ossorio, R Sarmento E Castro, R Granados, J Macías, L E Morano-Amado, M J Ríos, D Merino, E N Álvarez, A Collado, M Pérez-Pérez, F Téllez, J M Martín, J Méndez, J A Pineda, K Neukam
Little data are available on renal toxicity exerted by direct-acting antivirals (DAAs) in real life. The aim of this study was to assess the impact of direct-acting antivirals against hepatitis C virus infection currently used in Spain and Portugal on the estimated glomerular filtration rate (eGFR) in clinical practise. From an international, prospective multicohort study, patients treated with DAAs for at least 12 weeks and with eGFR ≥30 mL/min per 1.73 m2 at baseline were selected. eGFR was determined using the CKD-EPI formula...
January 28, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29359019/impact-of-sustained-virologic-response-on-chronic-kidney-disease-progression-in-hepatitis-c
#16
Elizabeth S Aby, Tien S Dong, Jenna Kawamoto, Joseph R Pisegna, Jihane N Benhammou
AIM: To determine how sustained virological response at 12 wk (SVR12) with direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection affects chronic kidney disease (CKD) progression. METHODS: A retrospective analysis was performed in patients aged ≥ 18 years treated for HCV with DAAs at the VA Greater Los Angeles Healthcare System from 2014-2016. The treatment group was compared to patients with HCV from 2011-2013 who did not undergo HCV treatment, prior to the introduction of DAAs; the control group was matched to the study group in terms of age, gender, and ethnicity...
December 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/29337400/immunization-in-end-stage-renal-disease-the-perception-of-waiting-list-patients
#17
Leonardo Figueiredo Camargo, Alessandra Martins Lother, Marilda Mazzali, Raquel S B Stucchi
BACKGROUND: The number of patients with chronic kidney disease is increasing worldwide, as well as the number of patients in kidney transplant waiting lists. In order to prevent infections related to immunosuppressive therapy, immunization guidelines for CKD patients before transplantation have been proposed. The aim of the present study was to evaluate adherence to immunization in a cohort of CKD patients in transplant waiting list and their renal replacement therapy clinics. METHODS: CKD patients older than 18 years old, receiving renal replacement therapy longer than 12 months and included in kidney transplant waiting list at University of Campinas (Unicamp) were enrolled...
January 16, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29328026/clinical-efficacy-of-s-adenosylmethionine-in-patients-with-non-alcoholic-steatohepatitis-and-chronic-kidney-disease-i-ii-stage
#18
A Antoniv, N Antofiychuk, T Danylyshina, I Trefanenko, V Shuper
The article presents a theoretical generalization of the results of the clinical efficacy of S-adenosylmethionine in patients with non-alcoholic steatohepatitis (NASH) in comorbidity with obesity and chronic kidney disease (CKD) of the 1st-2nd stages. The objective of the article was to determine the likely effect of S-adenosylmethionine and Meldonium on the clinical course of non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) of the I-II stages. We examined 75 patients with NASH with comorbid obesity I degree and CKD I and II dgrees...
December 2017: Georgian Medical News
https://www.readbyqxmd.com/read/29327401/daclatasvir-and-reduced-dose-sofosbuvir-an-effective-and-pangenotypic-treatment-for-hepatitis-c-in-patients-with-egfr-30-ml-min
#19
Amit Goel, Dharmendra Singh Bhadauria, Anupma Kaul, Prashant Verma, Mayank Mehrotra, Amit Gupta, Raj Kumar Sharma, Praveer Rai, Rakesh Aggarwal
BACKGROUND & AIMS: Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) <30 mL/min. We report real-life experience of treating a cohort of CKD patients with eGFR <30 mL/min using daclatasvir and half-daily dose of sofosbuvir. METHODS: Adults patients who (i) had eGFR<30 ml/min and detectable HCV RNA and (ii) were treated with interferon and ribavirin free, DAA based regimens were included...
January 12, 2018: Nephrology
https://www.readbyqxmd.com/read/29316062/efficacy-and-safety-of-ombitasvir-paritaprevir-ritonavir-combination-therapy-for-genotype-1b-chronic-hepatitis-c-patients-complicated-with-chronic-kidney-disease
#20
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadashi Ikegami, Noritomo Shimada, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Hidenori Toyoda, Takashi Kumada, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
AIM: The aim of this study was to clarify the effects and safety of ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) therapy in genotype 1b chronic hepatitis C patients with non-dialysis chronic kidney disease (CKD). METHODS: This retrospective, multicenter study of 12-week OBT/PTV/r therapy included genotype 1b patients with non-dialysis CKD. Chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 . Virologic responses and treatment-emergent adverse events (TEAEs) in patients with CKD were compared with those in patients without CKD...
January 9, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
keyword
keyword
26434
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"